Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors
- 16 January 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (2) , 1500-1512
Abstract
Casitas B-lymphoma proto-oncogene-b (Cbl-b), a member of the Cbl family of RING finger E3 ubiquitin ligases, has been demonstrated to play a central role in regulating effector T-cell function. Multiple studies using gene-targeting approaches have provided direct evidence that Cbl-b negatively regulates T, B, and NK cell activation via a ubiquitin-mediated protein modulation. Thus, inhibition of Cbl-b ligase activity can lead to immune activation and has therapeutic potential in immuno-oncology. Herein, we describe the discovery and optimization of an arylpyridone series as Cbl-b inhibitors by structure-based drug discovery to afford compound 31. This compound binds to Cbl-b with an IC50 value of 30 nM and induces IL-2 production in T-cells with an EC50 value of 230 nM. Compound 31 also shows robust intracellular target engagement demonstrated through inhibition of Cbl-b autoubiquitination, inhibition of ubiquitin transfer to ZAP70, and the cellular modulation of phosphorylation of a downstream signal within the TCR axis.Keywords
This publication has 37 references indexed in Scilit:
- Releasing the Brake: Targeting Cbl-b to Enhance Lymphocyte Effector FunctionsJournal of Immunology Research, 2012
- Autoinhibition and phosphorylation-induced activation mechanisms of human cancer and autoimmune disease-related E3 protein Cbl-bProceedings of the National Academy of Sciences, 2011
- Essential Role of E3 Ubiquitin Ligase Activity in Cbl-b–Regulated T Cell FunctionsThe Journal of Immunology, 2011
- Cbl-b and Itch: Key Regulators of Peripheral T-cell ToleranceCancer Research, 2010
- Ubiquitylation in innate and adaptive immunityNature, 2009
- Ablation of Cbl-b provides protection against transplanted and spontaneous tumorsJournal of Clinical Investigation, 2007
- Spontaneous tumor rejection by cbl-b–deficient CD8+ T cellsJournal of Experimental Medicine, 2007
- E3 ubiquitin ligases as T cell anergy factorsNature Immunology, 2004
- c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulationNature Immunology, 2002
- Tyrosine phosphorylation and complex formation of Cbl-b upon T cell receptor stimulationOncogene, 1999